StemCell Therapy

PORTLAND, Maine, May 16, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2023 Annual Meeting of Stockholders will be conducted virtually.

Follow this link:
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

Snow invited to share space manufacturing experience Snow invited to share space manufacturing experience

See the article here:
Eascra Biotech CEO Speaking at Global Synthetic Biology Conference

This authorization is the first authorized treatment of a patient with MDMA outside of a clinical trial in Canadian history This authorization is the first authorized treatment of a patient with MDMA outside of a clinical trial in Canadian history

Originally posted here:
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Paris and Saint-Quentin-Fallavier, France, May 16, 2023 – eureKING (ISIN: FR0014009ON9, Euronext Paris), the first European special purpose acquisition company (“SPAC”) in healthcare dedicated to bioproduction, today announced that it has submitted a firm offer on the basis of which it has been granted an exclusivity period with a view to acquiring Skyepharma, an innovative and fully integrated French CDMO player with 20 years of innovation and development experience in drug development and delivery of oral technologies.

View original post here:
eureKING, the first European SPAC in healthcare dedicated to biomanufacturing, announces its intention to combine with Skyepharma to build a new...

KRAKOW, Poland, May 16, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

See the article here:
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Excerpt from:
Monthly information related to total number of voting rights and shares composing the share capital _May 15, 2023

Daix (France), Long Island City (New York, United States), May 16, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported financial information for the first quarter of 2023, including its cash, cash equivalents and revenues, and provided a corporate update.

Visit link:
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

BRISBANE, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 15, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).

Here is the original post:
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the three months ended March 31, 2023.

Read the rest here:
Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023

~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01)

More:
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in...

Call scheduled for Thursday, June 22nd at 4:30 pm Eastern Time Call scheduled for Thursday, June 22nd at 4:30 pm Eastern Time

Read the original post:
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison’s Disease was presented at the 2023 World Congress on Parkison’s Disease and Related Disorders (IAPRD), held in Chicago, IL May 13-16, 2023.

See the original post here:
BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of...

DURHAM, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023.

View post:
Bioventus Reports First Quarter Financial Results

Michelle Robertson to remain with Company until August 16, 2023 Michelle Robertson to remain with Company until August 16, 2023

See the original post:
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

Company on track to complete planned interim analyses from two ongoing Phase 2 studies of the OCA-bezafibrate combination in 2023

View post:
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.

Original post:
IBT resolves on a rights issue

Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Friday June 9, 2023 at 10.00 CEST in the premises of the company at Bryggargatan 10, Stockholm.

Continue reading here:
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.

The rest is here:
CENTOGENE Reports Full Year 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million. All of the shares to be sold in the offering are being sold by Akero Therapeutics. The financing was led by new investor General Atlantic and included existing investors Adage Capital Partners LP, Avidity Partners, Boxer Capital, Commodore Capital, Janus Henderson Investors, Logos Capital, Perceptive Advisors, Rock Springs Capital and funds and accounts advised by T. Rowe Price Associates, Inc. The offering is expected to close on or about May 19, 2023, subject to the satisfaction of customary closing conditions.

Read this article:
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

Stay on top of your fur baby's health: the importance of scheduling routine vet visits  FoxReno.com

Originally posted here:
Stay on top of your fur baby's health: the importance of scheduling routine vet visits - FoxReno.com